全文获取类型
收费全文 | 541篇 |
免费 | 36篇 |
国内免费 | 28篇 |
专业分类
儿科学 | 15篇 |
妇产科学 | 8篇 |
基础医学 | 50篇 |
口腔科学 | 3篇 |
临床医学 | 131篇 |
内科学 | 163篇 |
皮肤病学 | 2篇 |
神经病学 | 19篇 |
特种医学 | 72篇 |
外科学 | 48篇 |
综合类 | 10篇 |
预防医学 | 15篇 |
眼科学 | 4篇 |
药学 | 42篇 |
肿瘤学 | 23篇 |
出版年
2021年 | 5篇 |
2020年 | 3篇 |
2019年 | 4篇 |
2018年 | 9篇 |
2017年 | 4篇 |
2016年 | 11篇 |
2015年 | 10篇 |
2014年 | 4篇 |
2013年 | 29篇 |
2012年 | 20篇 |
2011年 | 18篇 |
2010年 | 18篇 |
2009年 | 22篇 |
2008年 | 18篇 |
2007年 | 31篇 |
2006年 | 21篇 |
2005年 | 26篇 |
2004年 | 26篇 |
2003年 | 19篇 |
2002年 | 19篇 |
2001年 | 18篇 |
2000年 | 13篇 |
1999年 | 15篇 |
1998年 | 19篇 |
1997年 | 18篇 |
1996年 | 19篇 |
1995年 | 20篇 |
1994年 | 15篇 |
1993年 | 24篇 |
1992年 | 13篇 |
1991年 | 11篇 |
1990年 | 15篇 |
1989年 | 13篇 |
1988年 | 14篇 |
1987年 | 10篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 7篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1973年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有605条查询结果,搜索用时 15 毫秒
101.
Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia 总被引:1,自引:1,他引:0 下载免费PDF全文
Savani BN Rezvani K Mielke S Montero A Kurlander R Carter CS Leitman S Read EJ Childs R Barrett AJ 《Blood》2006,107(4):1688-1695
Eighty patients with chronic myeloid leukemia (CML) underwent T cell-depleted stem cell transplantation from an HLA-identical sibling, with add-back of donor T cells on days 30 to 45 and days 60 to 100 in patients in whom grade 2 or greater acute graft-versus-host disease (GVHD) developed. The outcomes for 54 patients with chronic-phase (CP) and 26 with advanced-phase (AP) disease were as follows: overall survival, 85% +/- 5% versus 36% +/- 10%; transplantation-related mortality (TRM), 13% +/- 5% versus 43% +/- 11%; and current leukemia-free survival, 76% +/- 6% versus 34% +/- 9%. The day-30 lymphocyte count (LC30) was strongly associated with outcome. For patients in CP with counts greater than the median of 0.30 x 10(9)/L, survival was 100% versus 70% +/- 9% (P = .003); current LFS 100% versus 56% +/- 9% (P = .002); and TRM 0% versus 26% +/- 8% (P = .006). Higher-than-median LC30 correlated significantly with molecular remission (MR) at 3, 6, and 12 months and with higher CD34 doses. Lymphocyte subset analysis performed in 20 patients available for phenotyping showed that LC30 was highly correlated with absolute CD56+CD3- natural killer cell numbers (NK30), which also predicted for survival and MR. CD34 cell dose, LC30, and NK30, but not day-30 CD3+ cell count, were highly correlated and were significant predictors of transplantation outcome. These results suggest that transplanted CD34 cell doses greater than 5 x 10(6)/kg may improve outcomes by increasing the early recovery of NK cells. 相似文献
102.
103.
104.
105.
Hypersensitivity pneumonitis: evaluation with CT 总被引:4,自引:0,他引:4
Thirteen chest radiographs and computed tomographic (CT) scans obtained from 11 patients with hypersensitivity pneumonitis were reviewed. The CT findings were correlated with open lung biopsy findings in seven patients. The two patients with acute hypersensitivity pneumonitis showed air-space opacification on CT scans. An open lung biopsy, done in one of these patients, demonstrated noncaseating granulomas and filling of the air spaces with macrophages. The nine patients with subacute hypersensitivity pneumonitis showed small, rounded opacities and patchy air-space opacification on CT scans. These findings reflected the histologic findings, which consisted of interstitial pneumonitis, cellular bronchiolitis, and small, noncaseating granulomas. The six patients with symptoms for 12 months or longer also showed irregular linear opacities on CT scans, corresponding to areas of fibrosis. CT scans were superior to radiographs in helping to assess the type and extent of abnormalities, and high-resolution CT scans were superior to conventional CT scans. 相似文献
106.
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. 总被引:43,自引:25,他引:18 下载免费PDF全文
R Childs E Clave N Contentin D Jayasekera N Hensel S Leitman E J Read C Carter E Bahceci N S Young A J Barrett 《Blood》1999,94(9):3234-3241
Nonmyeloablative allogeneic stem cell transplantation has recently been explored as a safer alternative to conventional high-dose transplant regimens. Although a high incidence of mixed chimerism after nonmyeloablative procedures has been reported, the exact kinetics of engrafting donor cells in specific cellular lineages has yet to be defined. We investigated lineage-specific chimerism in 15 patients receiving an allogeneic peripheral blood stem cell (PBSC) transplant from an HLA-identical (n = 14) or a 5/6 antigen-matched sibling donor after a preparative regimen of cyclophosphamide and fludarabine. Donor chimerism was assessed weekly in T lymphocytes and myeloid cells by polymerase chain reaction (PCR) of minisatellite regions. Eight patients survived between 121 to 409 days after transplant. Ten of 14 patients surviving more than 30 days (71.4%) had delayed disease regression consistent with a graft-versus-malignancy (GVM) effect. One patient rejected the transplant with subsequent recovery of autologous hematopoiesis. Hematological recovery was rapid (median, 11 days to >/=500 neutrophils/microL) and was initially predominantly recipient in origin. Donor myeloid chimerism gradually supplanted recipient hematopoiesis and became fully donor in all survivors by 200 days after transplantation. In contrast, T-cell engraftment was more rapid, with full chimerism in 7 patients by day 30 and in 6 further patients by day 200 after cyclosporine withdrawal and donor lymphocyte infusion. Full donor T-cell engraftment preceded donor myeloid engraftment, acute graft-versus-host disease, and disease regression, consistent with a requirement for 100% donor T-cell chimerism for full expression of the alloresponse. These results emphasize the importance of lineage-specific chimerism analysis to successfully manipulate engraftment after nonmyeloablative allogeneic PBSC transplantation. 相似文献
107.
DNA microarray technology for neonatal screening 总被引:2,自引:0,他引:2
SF Dobrowolski RA Banas EW Naylor T Powdrill D Thakkar 《Acta paediatrica (Oslo, Norway : 1992)》1999,88(S432):61-64
Modern molecular biology, owing much to the Human Genome Initiative, has elucidated many of the genetic mechanisms underlying heritable metabolic disease. While the use of molecular methods has flourished in research laboratories, complexity and cost have limited their utility in newborn screening. Newborn blood cards provide high quality DNA samples able to provide reliable support to highly multiplexed polymerase chain reactions (PCR). New manufacturing processes have reduced the cost of DNA microarray technology to the point where it is a practical tool for population screening. In a single assay, a DNA microarray facilitates the co-detection of amplification products diagnostic for several genetic diseases. High throughput is achieved with automation at every step, from DNA extraction to detection of hybrids. We suggest that it is both feasible and practical to develop a first-tier newborn screening protocol based upon multiplex PCR and analysis of amplification products using DNA microarrays. Initial data utilizing the model systems of sickle cell disease, α-1-antitrypsin deficiency and Factor V Leiden will be reported. 相似文献
108.
109.
110.